U.S. Markets closed

Acceleron Pharma Inc. (XLRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
116.77-3.24 (-2.70%)
At close: 4:00PM EST

116.77 0.00 (0.00%)
After hours: 4:04PM EST

Acceleron Pharma Inc.

128 Sidney Street
Cambridge, MA 02139
United States
617 649 9200
http://www.acceleronpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees237

Key Executives

NameTitlePayExercisedYear Born
Mr. Habib J. DableCEO, Pres & Director1.02MN/A1969
Dr. Thomas P. ManiatisCo-Founder, Member of Scientific Advisory Board & Director Emeritus22.5kN/A1943
Mr. Kevin F. McLaughlinSr. VP, CFO & Treasurer603.93kN/A1956
Dr. Ravindra KumarChief Scientific Officer & Sr. VP543.06kN/A1960
Mr. Sujay R. KangoExec. VP & Chief Commercial Officer595.54kN/A1964
Dr. Mark PtashneCo-Founder and Member of Scientific Advisory BoardN/AN/AN/A
Ms. Lisa WymanSr. VP of Technical OperationsN/AN/AN/A
Mr. Todd James IRCSr. VP of Corp. Affairs & Investor RelationsN/AN/AN/A
Mr. Adam M. Veness Esq.Sr. VP, Gen. Counsel & Sec.N/AN/A1986
Mr. Matthew S. FearerDirector of Corp. CommunicationsN/AN/A1966
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Acceleron Pharma Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.